NCT06921746 Changes in the Urinary Microbiome and Metabolome During Treatment of the Overactive Bladder in Female Patients
| NCT ID | NCT06921746 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital Ostrava |
| Condition | Overactive Bladder |
| Study Type | OBSERVATIONAL |
| Enrollment | 80 participants |
| Start Date | 2025-05-01 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 80 participants in total. It began in 2025-05-01 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a non-interventional study that will not pose any burden for the participants. The study subjects will be examined and treated in a standard manner according to current clinical recommendations for the treatment of overactive bladder (OAB). A portion of urine samples, which are routinely collected for biochemical and culture examinations as part of the diagnostic process, will be sent for examination of the characteristics of the urinary microbiome and metabolome (UMM) before and after treatment.
Eligibility Criteria
Inclusion Criteria: * Adult women over 18 years of age * Written consent to participate in the study * Willingness to undergo OAB evaluation and treatment according to the protocol * OAB symptoms lasting longer than 3 months * At least 3 episodes of severe urgency with or without urge incontinence within 3 days documented by voiding diary * OAB symptom score V8 questionnaire ≥ 8 Exclusion Criteria: * Known congenital developmental defects of the urinary tract (congenital hydronephrosis, vesicoureteral reflux, renal agenesis and hypoplasia, multicystic and polycystic kidneys) * Any previous treatment for OAB * Recurrent urinary tract infections (more than 3 episodes in the last 12 months) * Presence of a foreign body in the urinary tract - urolithiasis, urinary catheter, ureteral stent * Acute or chronic diseases with possible influence on the function of the lower urinary tract (LUT) * Rheumatoid arthritis * Diabetes mellitus
Contact & Investigator
Jan Krhut, prof., MD, PhD
PRINCIPAL INVESTIGATOR
University Hospital Ostrava
Frequently Asked Questions
Who can join the NCT06921746 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Overactive Bladder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06921746 currently recruiting?
Yes, NCT06921746 is actively recruiting participants. Contact the research team at jiri.hyncica@fno.cz for enrollment information.
Where is the NCT06921746 trial being conducted?
This trial is being conducted at Ostrava, Czechia, Prague, Czechia, Prague, Czechia, Prague, Czechia.
Who is sponsoring the NCT06921746 clinical trial?
NCT06921746 is sponsored by University Hospital Ostrava. The principal investigator is Jan Krhut, prof., MD, PhD at University Hospital Ostrava. The trial plans to enroll 80 participants.